bioAffinity Technologies, Inc. (NASDAQ:BIAF) Short Interest Up 33.4% in December

bioAffinity Technologies, Inc. (NASDAQ:BIAF) was the recipient of a large growth in short interest during the month of December. As of December 15th, there was short interest totalling 177,500 shares, a growth of 33.4% from the November 30th total of 133,100 shares. Based on an average daily trading volume, of 145,500 shares, the short-interest ratio is presently 1.2 days. Approximately 1.9% of the company’s stock are sold short.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in bioAffinity Technologies stock. Ground Swell Capital LLC bought a new position in shares of bioAffinity Technologies, Inc. (NASDAQ:BIAF) during the 2nd quarter, according to its most recent disclosure with the SEC. The fund bought 22,864 shares of the company’s stock, valued at approximately $49,000. Ground Swell Capital LLC owned 0.20% of bioAffinity Technologies at the end of the most recent quarter. 1.64% of the stock is currently owned by hedge funds and other institutional investors.

bioAffinity Technologies Stock Performance

NASDAQ BIAF traded down $0.06 during trading on Friday, reaching $0.89. 115,866 shares of the company’s stock were exchanged, compared to its average volume of 139,713. The business has a 50 day moving average price of $1.19 and a 200-day moving average price of $1.70. bioAffinity Technologies has a fifty-two week low of $0.83 and a fifty-two week high of $3.62. The stock has a market capitalization of $13.87 million, a P/E ratio of -1.09 and a beta of 2.85. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.02 and a quick ratio of 1.01.

bioAffinity Technologies Company Profile

bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level.